This invention relates to methods of increased the sensitivity of cancers such as melanoma to cytotoxic anti-cancer compounds such as methotrexate by inhibiting melanosome trafficking in the cancer cells for example using Akt2 signalling inhibitors such as 7-hydroxystraurosporine. Methods of treatment and compounds for use therein are provided.

Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 30 mg/ml. The invention also relates to a ready-made syringe and a carpule containing such a pharmaceutical solution formulation as well as a pen injector comprising such a carpule a...

The invention provides a method of treatment of melanoma comprising administering a tyrosinase expression enhancer, such as MTX, and a tyrosinase-activated prodrug, such as TMECG or TMCG, to an individual in need thereof. Also provided is a method of treating melanoma comprising administering a tyrosinase-activated prodrug and a compound for differentiating a stem-like tumor cell into a matured cell that is a tyrosinase producer to an individual in need thereof. Further provided is a method of t...

The present invention provides combinations of active agents such combinations comprising one or more antifolate compounds. The particularly can include methotrexate and one or more further antifolate compounds. In specific embodiments the combinations are useful for treating certain conditions such as rheumatoid arthritis. The invention also provides articles useful to provide the combinations in desirable dosage forms and combinations. The combinations further may be useful in the treatment of...

FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to experimental studies in oncology and may be used for assessing the anti-tumour action of metal nanoparticles (NP). An iron nanoparticle suspension 1.25 mg/kg is introduced into grafted Pliss lymphosarcoma intratumourally. That is followed by the paratumoural introduction of methotrexate 0.2 mg/kg. The tumour is locally heated to temperature 42-43 DEG C using an electromagnetic UHF emission at frequency 12.7 MHz for 10 minutes. Th...

The present invention describe methods and compositions for treating diverse dermatological conditions,including acne and psoriasis, using zein containing nanocarrier devices for topical delivery of methotrexate, retinoic acid and benzoyl peroxide to select targets in the skin.